CTD Holdings Submits Application for Listing on NASDAQ

World News: . []

ALACHUA, FL, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has submitted its application to list its common stock on the NASDAQ Capital Market.

The Company’s management has completed the application and submitted the request to list on The . The listing of the Company’s common shares remains subject to the approval of NASDAQ and the satisfaction of all applicable listing standards, including the minimum share price requirement.

As more information becomes available, the Company will update the progress on its intended up-listing accordingly. 

"We are excited to take this next step in the maturation of our company," said N. Scott Fine, CTD's Chairman of the Board and CEO. "Listing on NASDAQ will allow additional investors to support the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C and other indications.”

Trappsol® Cyclo™, CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, is currently being evaluated at clinical sites in the U.S., Israel, the UK, and Sweden for treatment of NPC, a rare genetic disease that causes neurologic, liver, lung and other organ dysfunction and that is ultimately fatal.

Wendy Tanaka (415) 369-8447 wtanaka@sitrick.com 

More news and information about CTD Holdings, Inc.

Published By:

Globe Newswire: 17:53 GMT Wednesday 12th June 2019

Published: .

Search for other references to "holdings" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us